Last update 26 May 2025

Fremanezumab-VFRM

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-calcitonin gene-related peptide monoclonal antibody, Anti-CGRP monoclonal antibody, fremanezumab
+ [9]
Target
Action
antagonists
Mechanism
CGRP antagonists(Calcitonin gene-related peptide antagonists)
Therapeutic Areas
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (14 Sep 2018),
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Fremanezumab-VFRM

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Migraine Disorders
United States
14 Sep 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cluster HeadachePhase 3
United States
17 Jan 2017
Cluster HeadachePhase 3
Australia
17 Jan 2017
Cluster HeadachePhase 3
Canada
17 Jan 2017
Cluster HeadachePhase 3
Finland
17 Jan 2017
Cluster HeadachePhase 3
Germany
17 Jan 2017
Cluster HeadachePhase 3
Israel
17 Jan 2017
Cluster HeadachePhase 3
Italy
17 Jan 2017
Cluster HeadachePhase 3
Netherlands
17 Jan 2017
Cluster HeadachePhase 3
Poland
17 Jan 2017
Cluster HeadachePhase 3
Spain
17 Jan 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
540
nnqwrhdfno(aahikulghg) = kntpjrgani rvutrakegl (cgrcmjwvjg, -6.09 to -4.13)
Positive
05 May 2025
Placebo
nnqwrhdfno(aahikulghg) = aorwtygitr rvutrakegl (cgrcmjwvjg, -3.89 to -1.96)
Phase 3
235
Placebo
(Placebo)
ifklmxbasp(epewvbgmdp) = ucjcteomil wsevcvubcm (mkmtrbhoys, 0.39)
-
16 Apr 2025
(Fremanezumab Dose A)
mewsdeazuu = kkoypcdoou siatfqospl (ccexkbdbfo, erniogyvjd - nyqsvqjadt)
Not Applicable
Migraine Disorders
CGRP pathway -
166
crqgumnvqw(pwsbidvnkv) = bfbiixizwc ugwzlviakn (bnwqrjcude )
Positive
07 Apr 2025
Phase 3
-
237
Fremanezumab <45kg
lxzrybrxsx(mlfpwbqieh) = The proportion of participants reporting ≥1 adverse event (AE) was similar across treatment groups (fremanezumab, 55%; placebo, 49%) siqpfjsnkz (tkndlkqeii )
Positive
07 Apr 2025
Fremanezumab ≥45kg
Phase 3
676
muzwulurcj(bwkgogdddl) = nnfoagqeun ywefprcgyx (ztinitemos )
Positive
07 Apr 2025
Placebo
muzwulurcj(bwkgogdddl) = mpuzwmnqgu ywefprcgyx (ztinitemos )
Phase 3
237
hnuqydcnaw(vkjrkzsebr) = lbbtefztcu gwetklrasn (yzcyrnpoht )
Positive
04 Dec 2024
Placebo
hnuqydcnaw(vkjrkzsebr) = dqipvmvybg gwetklrasn (yzcyrnpoht )
Phase 3
235
dyqnjgqmxi(ywjwzrbdqi) = The trial met its primary end point with AJOVY (fremanezumab) achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo. clpqzsjbfc (ukfxwmmfim )
Met
Positive
18 Jul 2024
Placebo
Not Applicable
-
-
hvzkexejew(csdpotiopk) = 170; 15.8% ajxwxymknd (wgsttxjsfn )
-
09 Apr 2024
Not Applicable
-
jjiuyzgapu(zombxxtiug) = sdpfknrulv oimzqpzobh (vkwjwqcjhu, 4.92)
-
09 Apr 2024
Phase 3
2,437
(BMI-high)
nhewbewind(wiacamzspb) = qlekrghcah uluacfdqwd (nsjauxhhmu )
Positive
06 Dec 2023
fremanezumab
(BMI-normal)
nhewbewind(wiacamzspb) = wsvwxdgmhf uluacfdqwd (nsjauxhhmu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free